Intravenous (iv) abatacept (DrugBank: Abatacept)
26 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
11 | Myasthenia | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
19 | Lysosomal storage disease | 0 |
41 | Giant cell arteritis | 0 |
44 | Wegener granulomatosis | 0 |
46 | Malignant rheumatoid arthritis | 2 |
49 | Systemic lupus erythematosus | 0 |
50 | Dermatomyositis | 0 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
55 | Relapsing polychondritis | 0 |
60 | Aplastic anemia | 0 |
65 | Primary immunodeficiency | 0 |
84 | Sarcoidosis | 0 |
93 | Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
107 | Juvenile idiopathic arthritis [Systemic juvenile idiopathic arthritis (~Mar 2018)] | 0 |
160 | Congenital ichthyosis | 0 |
164 | Oculocutaneous albinism | 0 |
222 | Primary nephrotic syndrome | 0 |
271 | Ankylosing spondylitis | 0 |
284 | Diamond-Blackfan anemia | 0 |
285 | Fanconi anemia | 0 |
300 | IgG4-related disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01001832 (ClinicalTrials.gov) | December 2009 | 26/10/2009 | Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients | A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate | Rheumatoid Arthritis | Drug: Intravenous (IV) abatacept;Drug: Subcutaneous (SC) abatacept | Bristol-Myers Squibb | NULL | Completed | 20 Years | N/A | All | 118 | Phase 2;Phase 3 | Japan |
2 | NCT00559585 (ClinicalTrials.gov) | January 2008 | 15/11/2007 | Methotrexate-Inadequate Response Study | A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate | Rheumatoid Arthritis (RA) | Drug: Subcutaneous (SC) Abatacept;Drug: Intravenous (IV) Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 2492 | Phase 3 | United States;Argentina;Australia;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Taiwan;Turkey;United Kingdom;Austria;Spain |